Akros SCHK HK-U.S. Biotech Index

Johnson & Johnson is scheduled to report third-quarter 2026 results on October 13, 2026, with published consensus EPS estimates of approximately $3.02-$3.04.

Thomas Dittrich is scheduled to become Amgen's executive vice president and chief financial officer on September 1, 2026, succeeding retiring CFO Peter Griffith.

The FDA is scheduled to decide on Bristol Myers Squibb's NDA for iberdomide with daratumumab and dexamethasone in relapsed or refractory multiple myeloma on August 17, 2026.

Eli Lilly will announce second-quarter 2026 financial results and hold its earnings call on August 5, 2026.

Amgen has officially scheduled its Q2 2026 earnings conference call for August 4, 2026 at 1:30 p.m. PDT, following the U.S. market close.

Gilead is scheduled to release second-quarter 2026 financial results and guidance after the market closes on August 4, 2026.

Merck is scheduled to release second-quarter 2026 sales and earnings and hold its investor conference call on August 4, 2026.

Pfizer is scheduled to issue its Second Quarter 2026 Performance Report on the morning of August 4, 2026.

Merck is scheduled to hold a virtual HIV Investor Event on August 3, 2026, at which senior management will update investors on the company’s HIV program and strategy.

AbbVie is scheduled to release second-quarter 2026 financial results before the U.S. market opens on July 31, 2026, followed by an 8:00 a.m. CDT earnings webcast.

Bristol Myers Squibb is scheduled to report second-quarter 2026 financial results on July 30, 2026.

Genmab and AbbVie clarified that EPCORE DLBCL-1 did not meet its sole U.S. primary endpoint because epcoritamab monotherapy did not significantly improve overall survival versus investigator's-choice chemoimmunotherapy.

Amgen submitted data and analyses to the FDA on July 23, 2026 in support of a hearing request challenging CDER's proposed withdrawal of TAVNEOS approval.

EMA’s CHMP adopted a positive opinion recommending EU authorization of Trodelvy plus Keytruda for first-line PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer.

Johnson & Johnson reported positive Phase 3 MonumenTAL-6 topline results for TECVAYLI plus TALVEY in earlier-line relapsed or refractory multiple myeloma.

Eli Lilly reported positive Phase 3 TRIUMPH-2 and TRIUMPH-3 topline results for retatrutide, with a U.S. BLA submission planned for the first quarter of 2027.

A U.S. magistrate judge ordered plaintiffs in Johnson & Johnson's federal talc ovarian-cancer MDL to show that they can present admissible case-specific causation evidence or face dismissal of their claims.

Johnson & Johnson received FDA De Novo authorization for the OTTAVA robotic surgical system in the United States.

The FDA accepted Pfizer's TALZENNA plus XTANDI supplemental application for Priority Review in HRR gene-altered metastatic castration-sensitive prostate cancer.

Amgen agreed to a proposed $74 million settlement of an investor class action concerning disclosures of its potential IRS tax liability.

Gilead and Merck announced detailed 48-week Phase 3 results showing once-weekly islatravir/lenacapavir maintained virologic suppression in the ISLEND-1 and ISLEND-2 trials.

Gilead reported 52-week open-label-extension data from PURPOSE 1 and PURPOSE 2 showing sustained efficacy, high adherence, and no new safety signals for twice-yearly lenacapavir PrEP.

Merck and Gilead reported that once-weekly oral islatravir/lenacapavir maintained virologic suppression at Week 48 in both Phase 3 ISLEND trials.